Recursion Pharmaceuticals, Inc. - Class A Common Stock (RXRX)
4.5700
-0.0600 (-1.30%)
NASDAQ · Last Trade: Sep 4th, 3:05 PM EDT
Detailed Quote
Previous Close
4.630
Open
4.600
Bid
4.560
Ask
4.570
Day's Range
4.460 - 4.620
52 Week Range
3.790 - 12.36
Volume
11,708,522
Market Cap
769.71M
PE Ratio (TTM)
-2.511
EPS (TTM)
-1.8
Dividend & Yield
N/A (N/A)
1 Month Average Volume
17,110,642
Chart
About Recursion Pharmaceuticals, Inc. - Class A Common Stock (RXRX)
Recursion Pharmaceuticals Inc is a biotechnology company focused on leveraging advanced computational biology and machine learning techniques to transform drug discovery and development. By utilizing a proprietary platform that integrates high-throughput biology and data science, the company aims to identify new therapeutic targets and accelerate the process of discovering novel medicines for a variety of diseases. Their innovative approach seeks to uncover hidden connections in biological data, enabling them to explore previously uncharted areas in the pharmaceutical landscape and bring forth breakthrough treatments for patients in need. Read More
Nvidia's six-stock portfolio of publicly traded AI stocks was worth $4.3 billion at the end of the second quarter, and the company also owns stakes in many privately held AI start-ups.
Salt Lake City, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences:
The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy consumption of AI data centers is putting unprecedented strain on power grids and catalyzing a new wave of investment across traditional and
Recursion reported second-quarter revenue of $19.22 million, beating analyst estimates of $16.23 million, according to Benzinga Pro. The company reported a second-quarter loss of 41 cents per share, missing estimates for a loss of 34 cents per share.
Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7)
The digital landscape is undergoing a profound transformation as personalized AI, particularly generative AI models, are increasingly being fine-tuned to individual preferences and histories. This shift moves beyond generic interactions, creating highly tailored and dynamic digital environments that promise to revolutionize user experience across entertainment, e-commerce, and healthcare. The immediate
Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants.
